DCGO
DocGo Inc.
DCGO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over DCGO overall, supported by stronger fundamentals and lower modeled downside.
DCGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
DCGO's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DCGO PE Valuation
DCGO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
DCGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DCGO's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over DCGO on the outlook, with more favorable revenue expectations.
DCGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.84 | -$1.33 |
| Q2 2026 | -$1.95 | -$1.77 |
| Q1 2026 | -$1.90 | -$1.89 |
| Q4 2025 | -$1.84 | -1122% |
| Q3 2025 | -$0.51 | -289% |
| Q2 2025 | -$0.18 | -167% |
| Q1 2025 | -$0.01 | -105% |
| Q4 2024 | $0.18 | +200% |
DCGO lost $1.84 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over DCGO on earnings quality, reporting a profit while its opponent remains loss making.
DCGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +3.7% |
| Q2 2026 | $73.4M | -8.7% |
| Q1 2026 | $75.6M | -21% |
| Q4 2025 | $74.9M | -38% |
| Q3 2025 | $70.8M | -49% |
| Q2 2025 | $80.4M | -51% |
| Q1 2025 | $96M | -50% |
| Q4 2024 | $120.8M | -39% |
DCGO's revenue has slid since its 2023 peak: $73M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +36 points |
| Q2 2026 | -24% | -2.7 points |
| Q1 2026 | -25% | -10 points |
| Q4 2025 | -140% | -133 points |
| Q3 2025 | -59% | -67 points |
| Q2 2025 | -22% | -28 points |
| Q1 2025 | -15% | -23 points |
| Q4 2024 | -6.2% | -12 points |
DCGO's operating margin was −24% last quarter, up 36 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DCGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over DCGO on profitability, with a higher operating margin.
DCGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.7M | -578% |
| Q2 2026 | -$9.6M | -129% |
| Q1 2026 | -$5.1M | -162% |
| Q4 2025 | -$12M | -200% |
| Q3 2025 | $782.6K | -97% |
| Q2 2025 | $32.9M | +2.1% |
| Q1 2025 | $8.2M | +$19.8M |
| Q4 2024 | $12M | +$21.1M |
DCGO's free cash flow was −$30M over the past year, against $54M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over DCGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +137K shares |
| 1 year | +1.2% | +1.1M shares |
| 3 years | -5.8% | -6.1M shares |
| 5 years | -1.1% | -1.1M shares |
DCGO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $5.1M |
| Q1 2025 | $5.8M |
| Q4 2024 | $2.7M |
DCGO hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DCGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -3.5x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
| Q3 2024 | -1.6x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -8.4x | Net Cash |
DCGO has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DCGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 4.2 | Oversold |
DCGO's weekly RSI is 28 (oversold) and its Stochastic is 4 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DCGO PE vs Healthcare Sector
| Metric | DCGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DCGO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DCGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.29 | 21% below |
| 20 week MA | $0.43 | 47% below |
| 50 week MA | $0.60 | 62% below |
| 100 week MA | $1.44 | 84% below |
| 200 week MA | $3.57 | 94% below |
DCGO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DCGO on trend strength, trading above more of its moving averages.
DCGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $10.4 | +0.8% |
| 2021 | $10.4 | $8.71 | -16% |
| 2022 | $8.71 | $6.91 | -21% |
| 2023 | $6.91 | $5.59 | -19% |
| 2024 | $5.59 | $4.38 | -22% |
| 2025 | $4.38 | $0.93 | -79% |
| 2026 YTD | $0.93 | $0.23 | -75% |
DCGO has finished five years in a row lower, and it's down 75% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DCGO on returns for 2026, with the stronger performance.